Detail of the clinical trial

Title of the trial A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia
EudraCT number 2011-006292-20
Protocol number GS-US-312-0115
Sponsor Gilead Sciences, Inc.,199 East Blaine Street,Seattle, WA,98102
Indications Oncology
Diagnosis chronic lymphocytic laukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2013
Date of approval by Institute (SÚKL) 19.9.2013
Date of approval by EC 18.7.2013
Date of initiation CT in ČR 14.2.2014
Date of ending CT in ČR 7.1.2019 (14.12.2018)
Sites Fakultní nemocnice Brno,Interní hematoonkologická klinika,Jihlavská 20,Brno,625 00
Fakultní nemocnice Hradec Králové,IV. Interní hematologická klinika,Sokolská 581,Hradec Králové,500 05
Fakultní nemocnice Ostrava,Klinika hematoonkologie,17. listopadu 1790,Ostrava - Poruba,708 52

‹‹ Back to list